To evaluate the role of PAD4 in neutrophil activation and trafficking in CIA, we used a selective oral PAD4 inhibitor (JBI-589) administered once daily starting after the onset of clinical RA at day 30 for 26 consecutive days. The gene discussed is PADI4; the disease is rheumatoid arthritis.